镥[177Lu]-DOTA-TATE治疗胃肠胰神经内分泌肿瘤:意大利前瞻性观察性研究(REAL-LU)的原理、设计与基线特征
REAL-LU是一项意大利多中心长期观察性研究,纳入161例不可切除/转移性胃肠胰神经内分泌肿瘤(GEP-NETs)患者,旨在评估镥[177Lu]-DOTA-TATE的真实世界疗效与安全性。预定中期分析显示患者平均年龄64.7±10.3岁,全部为转移性疾病,90.7%为IV期,61.6%作为二线治疗;患者特征与NETTER 1试验相似,但2级肿瘤比例更高(71%)。
要点
- REAL-LU研究纳入161例意大利GEP-NETs患者,评估[177Lu]Lu-DOTA-TATE真实世界疗效与安全性。
- 基线时全部患者为转移性疾病,肝转移占83.9%,90.7%为IV期,61.6%作为二线治疗。
- 患者特征与NETTER 1相似,但2级肿瘤比例更高(71%),更接近NETTER-2人群。
核心结论
- 意大利接受[177Lu]Lu-DOTA-TATE治疗的GEP-NETs患者特征与NETTER 1试验人群相似,但2级肿瘤比例更高(71%)。
- 就肿瘤分级而言,本研究队列似乎更接近NETTER-2研究人群,即G2或G3晚期GEP-NETs(Ki-67≥10%且≤55%)。
- 随着REAL-LU数据成熟,可期待进一步的有效性和安全性分析。
研究设计与样本
- REAL-LU是一项意大利多中心、长期观察性研究,纳入不可切除/转移性GEP-NETs且标准治疗进展的患者。
- 研究总时长约48个月,其中招募期12个月、随访期36个月。
- 主要目的是评估[177Lu]Lu-DOTA-TATE的无进展生存期有效性,次要目的包括安全性、健康相关生活质量影响及预后因素识别。
- 本文为招募结束时进行的预定中期分析,描述意大利处方[177Lu]Lu-DOTA-TATE的GEP-NETs患者特征,共161例可评估患者。
主要发现
- 161例可评估患者中,入组时平均年龄64.7±10.3岁,83.8%体检无临床疾病体征,多数有轻微疾病症状。
- 全部患者均有转移性疾病,最常见为肝转移(83.9%),中位转移部位数为2个。
- 90.7%患者为IV期,68.3%有≥1个靶病灶。
- [177Lu]Lu-DOTA-TATE主要作为二线治疗(61.6%)并在手术后使用(58.4%)。
- 基线生活质量评估显示功能水平高、症状水平低;50.0%患者入组时无症状。
临床怎么用
- 本研究描述的是意大利临床实践中[177Lu]Lu-DOTA-TATE的处方习惯和患者特征,原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [177Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [177Lu]Lu-DOTA-TATE treatment in Italy. REAL-LU is a multicentre, long-term observational study in patients with unresectable/metastatic GEP-NETs progressing on standard therapies in Italian clinical practice. A pre-specified interim analysis was performed at the end of the enrolment period, data from which are described herein. METHODS: Overall duration of REAL-LU will be approximately 48 months, with 12- and 36-month recruitment and follow-up periods, respectively. The primary objective is to evaluate [177Lu]Lu-DOTA-TATE effectiveness in terms of progression-free survival. Secondary objectives include safety, impact on HRQoL, and identification of prognostic factors. This pre-specified interim analysis describes patient profiles, at the end of enrollment, of those prescribed [177Lu]Lu-DOTA-TATE for GEP-NETs in Italy. RESULTS: Among 161 evaluable patients, mean age was 64.7 ± 10.3 years at study entry, 83.8% presented with no clinical signs of disease at physical examination, and most had minor disease symptoms. All patients had metastatic disease, most commonly in the liver (83.9%) with a median of two metastatic sites. In 90.7% of patients, the disease was stage IV, and 68.3% had ≥ 1 target lesion. [177Lu]Lu-DOTA-TATE was prescribed mainly as second-line therapy (61.6%) and following surgery (58.4%). HRQoL assessments revealed high levels of functioning and low levels of symptoms at baseline; 50.0% of patients were symptom-free at study entry. CONCLUSION: The characteristics of patients who received [177Lu]Lu-DOTA-TATE in Italy are similar to those of the GEP-NET population of NETTER 1 with trial but with a higher proportion of patients with a grade 2 (71%). With regard to the tumor grade profile, our study cohort appears to be closer to that of NETTER-2 study population which included patients with G2 or G3 advanced GEP-NETs (i.e. Ki-67 ≥ 10% and ≤ 55%). Further analysis of effectiveness and safety can be anticipated as REAL-LU data mature. STUDY REGISTRATION: ClinicalTrials.gov, NCT04727723; Study Registration Date: 25 January, 2021; https://clinicaltrials.gov/study/NCT04727723?cond=NCT04727723&rank=1.
引用
- Lastoria S, Rodari M, Sansovini M, et al. Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38772998. doi:10.1007/s00259-024-06725-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。